RecruitingNCT07413029

French National Cohort of Patients With PRSS1 Mutations


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

800 participants

Start Date

Nov 10, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The diagnosis of hereditary pancreatitis (PH) is based on a genetic criterion - detection of a mutation in the PRSS1 gene or on a genealogical criterion - the presence of chronic pancreatitis in at least 2 first-degree relatives or at least 3 relatives in the second degree, in the absence of other identified predisposing factors (notably chronic alcohol consumption). It is now recommended to seek PH in cases of pancreatitis of unknown origin in a young patient or with a family history. In this study, patients carrying a PRSS1 mutation will be identified from the patient lists of the three French genetics laboratories (Brest University Hospital, Cochin-Paris University Hospital, Lille University Hospital) carrying out PRSS1 gene analysis. Patients will be included by the doctors currently treating them. The aim of the study is to assess the incidence of pancreatic adenocarcinoma in the cohort and describe the natural history of hereditary pancreatitis linked to a mutation in PRSS1.


Eligibility

Inclusion Criteria2

  • Being a carrier of a known genetic mutation in the PRSS1 gene coding for cationic trypsinogen
  • Be followed in one of the participating centers

Exclusion Criteria1

  • Opposition to data collection, expressed by the patient or one of their legal representatives

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERcollecting their health data from their medical file and completing questionnaires.

Patients seen as part of their follow-up will be offered to participate in the study. Their participation will consist of collecting their health data from their medical file and completing questionnaires.


Locations(1)

REBOURS

Clichy-sous-Bois, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07413029


Related Trials